Pfizer reorganizes to handle aging consumers and patents

FILE - In this Nov. 23, 2015, file photo, the Pfizer logo is displayed at world headquarters in New York. Pfizer says it’s going to reorganize the company into three businesses. Pfizer Inc. said Wednesday, July 11, 2018, that a new hospital unit, which will be part of the innovative medicines business, will be for anti-infectives and sterile injectables. There will also be a consumer healthcare business and an off-patent branded and generic established medicines business. (AP Photo/Mark Lennihan, File)

Pfizer, reassessing future needs, reorganizes

NEW YORK — The drugmaker Pfizer, facing an aging population and shifting risks from the loss of patents, is reshaping its structure into three businesses.

The divisions, announced Wednesday, include Innovative Medicines, which will focus on biological science and a new hospital medicines business. An Established Medicines business will include sales for older drugs like the cholesterol pill Lipitor that have lost patent protection.

Lastly, the Consumer Healthcare business will handle over-the-counter medicines.

Innovative Medicines will bring in most of the company's revenue. Pfizer said the growth potential for that business is strong, due in part to an aging population that will create a growing demand for new medicines.

Pfizer Inc., based in New York, expects a significant reduction in the impact of patent protection losses after 2020 following the loss of exclusivity in the U.S. for the pain medicine Lyrica, which is anticipated to occur around December.

CEO Ian Read said in a prepared statement that the reorganization represents a "natural evolution" for Pfizer given the strength of the products they are currently selling and drugs that are in late-stage clinical development.

Read said earlier this year that he expects Pfizer to win 25 to 30 approvals for new medicines or new uses for existing ones through 2022.

The reorganization announced Wednesday will occur at the start of fiscal 2019. The company said it doesn't expect the moves to affect 2018 guidance.

Shares of Pfizer climbed 2 cents to $37.45 before markets opened Wednesday.

Related News

Medicaid estimate renews cost concerns over...

Aug 12, 2016

Government cost estimates for expanding Medicaid to millions more low-income people are increasing...

Studies shine light on mysterious placenta, how...

Aug 12, 2016

Placenta is most mysterious organ: Scientists don't know how this tissue that nourishes a fetus...

3 years into nation's hemp experiment, crop's...

Aug 12, 2016

Three years into the nation's hemp experiment, the crop's hazy market potential is starting to come...

Tepid retail sales lower expectations for US...

Aug 12, 2016

Tepid retail spending in July lowers expectations for US economic growth in coming months

US producer prices slid 0.4 percent in July

Aug 12, 2016

US producer prices fell last month by the biggest percentage since September, pulled down by...

Pressuring Trump, Clinton releases 2015 tax...

Aug 13, 2016

Hillary Clinton and her husband earned $10.6 million last year, according to a tax filing released...

Here at The World Agenda, we bring innovation to digital news for you to keep abreast of worldwide news instantly anywhere.

Contact us: sales[at]theworldagenda.com